Davis Polk advised the underwriters in connection with an SEC-registered offering by AMAG Pharmaceuticals, Inc. of $300 million aggregate principal amount of its 3.25% convertible senior…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
